Dr Stelios Papadopoulos: Is Biotech finally achieving the long awaited promise of commercial success?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Dr Stelios Papadopoulos: Is Biotech finally achieving the long awaited promise of commercial success?
Released on: January 20, 2014. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this interview, filmed at the Index Ventures Playground event, Dr Fintan Walton talks to Dr Stelios Papadopoulos, Co-Founder and Chairman of the Board of Exelixis Inc.
  • Summary
  • Transcript
  • Participants
  • Company
In this interview, filmed at the Index Ventures Playground event, Dr Fintan Walton talks to Dr Stelios Papadopoulos, Co-Founder and Chairman of the Board of Exelixis Inc. Stelios shares his views on the current state of the Biotech scene and talks through some of the current success stories in the industry and the challenges that those companies have had to face.
In this interview, filmed at the Index Ventures Playground event, Dr Fintan Walton talks to Dr Stelios Papadopoulos, Co-Founder and Chairman of the Board of Exelixis Inc. Stelios shares his views on the current state of the Biotech scene and talks through some of the current success stories in the industry and the challenges that those companies have had to face.
Dr Stelios Papadopolous
Exelixis Inc
Exelixis Inc
Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. In advancing our first product, COMETRIQ, from discovery to market, we have established an effective and integrated infrastructure that encompasses the entire biopharmaceutical development continuum. We are committed to excellence in all aspects of our work and are dedicated to improving the care and outcome of cancer patients.